about
MicroRNAs in flow-dependent vascular remodellingMIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitmentNeointimal smooth muscle cells display a proinflammatory phenotype resulting in increased leukocyte recruitment mediated by P-selectin and chemokinesMechanisms of monocyte recruitment in vascular repair after injuryCirculating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E.MicroRNA-126-5p promotes endothelial proliferation and limits atherosclerosis by suppressing Dlk1Intracoronary infusion of autologous bone marrow cells and left ventricular function after acute myocardial infarction: a meta-analysis.Lysophosphatidic acid in atherosclerotic diseasesEndothelial cells suppress monocyte activation through secretion of extracellular vesicles containing antiinflammatory microRNAs.Dexamethasone and restenosis after coronary stent implantation: new indication for an old drug?Chemokines: key regulators of mononuclear cell recruitment in atherosclerotic vascular disease.MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophagesSDF-1alpha-mediated tissue repair by stem cells: a promising tool in cardiovascular medicine?Endothelial Dicer promotes atherosclerosis and vascular inflammation by miRNA-103-mediated suppression of KLF4Chemokine-like functions of MIF in atherosclerosis.Adult progenitor cells in vascular remodeling during atherosclerosis.Chemokines in vascular dysfunction and remodeling.Myocardial regeneration by transplantation of modified endothelial progenitor cells expressing SDF-1 in a rat model.Virtual elastic sphere processing enables reproducible quantification of vessel stenosis at CT and MR angiography.MicroRNA-126, -145, and -155: a therapeutic triad in atherosclerosis?Pathogenic arterial remodeling: the good and bad of microRNAs.MicroRNAs and the response to injury in atherosclerosis.MicroRNA-mediated mechanisms of the cellular stress response in atherosclerosis.MicroRNA regulation of macrophages in human pathologies.MIF interacts with CXCR7 to promote receptor internalization, ERK1/2 and ZAP-70 signaling, and lymphocyte chemotaxis.Deposition of platelet RANTES triggering monocyte recruitment requires P-selectin and is involved in neointima formation after arterial injury.Differential roles of angiogenic chemokines in endothelial progenitor cell-induced angiogenesis.Double-edged role of the CXCL12/CXCR4 axis in experimental myocardial infarction.Lysophosphatidic acid receptors LPA1 and LPA3 promote CXCL12-mediated smooth muscle progenitor cell recruitment in neointima formation.CXCL12 promotes the stabilization of atherosclerotic lesions mediated by smooth muscle progenitor cells in Apoe-deficient mice.The microRNA-342-5p fosters inflammatory macrophage activation through an Akt1- and microRNA-155-dependent pathway during atherosclerosis.Involvement of JAM-A in mononuclear cell recruitment on inflamed or atherosclerotic endothelium: inhibition by soluble JAM-A.A small molecule CXCR4 antagonist inhibits neointima formation and smooth muscle progenitor cell mobilization after arterial injury.Hyperlipidemia-Induced MicroRNA-155-5p Improves β-Cell Function by Targeting Mafb.Dicer generates a regulatory microRNA network in smooth muscle cells that limits neointima formation during vascular repair.Blockade of keratinocyte-derived chemokine inhibits endothelial recovery and enhances plaque formation after arterial injury in ApoE-deficient mice.Peripheral CD34+ cells and the risk of in-stent restenosis in patients with coronary heart disease.Protective role of CXC receptor 4/CXC ligand 12 unveils the importance of neutrophils in atherosclerosis.The CXCR4 antagonist POL5551 is equally effective as sirolimus in reducing neointima formation without impairing re-endothelialisation.Mechanisms of MicroRNAs in Atherosclerosis.
P50
Q27002530-9F27474F-1120-4F95-B30A-48DFCBD557BDQ28298072-171476F3-5815-49FE-B1F7-CA34BF2AECE6Q28576953-714B30A3-0E5D-440D-A8AA-38165498D643Q28648014-9D385B69-B5EA-4F1E-A847-C8F4C9072B90Q30310323-5D8CC742-96AA-400C-9C1D-0BE90F754489Q30414327-4D4AD358-2D4B-45B5-A954-A9CAE6F4BBDEQ33258314-39E9A0B3-02DE-4D99-8413-ECF14A227A87Q34273486-65BF4391-FFDE-4372-9748-79EF9C4D880FQ35634914-79243292-832F-4C39-83C6-7791090FBA24Q35668026-E51B4493-107C-416B-9B43-7DDB26565E64Q35866628-652C2ABF-088A-4854-A73A-8D9BEDF16B0BQ36357815-5968096B-35B6-4118-8847-889BCF7B3668Q36483554-2C4BAD00-201E-4D80-8D67-7BB0F2375026Q36548746-B9C6278D-1108-4915-9D0A-6D647767FE69Q37127327-3E38AE18-34B8-4442-95E3-25F775CCBF0BQ37216602-C41D3805-BBCD-46B4-904F-ABCB89C92E8BQ37279675-0D46947A-AD6D-43FA-92F0-DF9573680535Q37296208-DE2D808F-75F4-45F6-93FD-5AA64E5C8CBBQ37905442-A20E5559-193F-4F7C-A7EC-7AFCF5D0B05AQ38074511-C76BD51F-98BD-42F8-BB71-5E4A262F362CQ38080410-C8E80F52-C443-43AD-A833-BD069AFADB6CQ38328880-EBDBEB28-90BE-4E88-A9FD-8919219E662CQ38412322-EA8CA37F-0AC5-4880-95D5-6A5A98684B19Q38823315-5BCA6E8D-6FAD-48CA-A06E-927063137411Q38857118-5A9DD14F-AE67-4D51-8F78-4F22C13CC1F1Q40703820-B3A7059C-1795-4450-AD0F-5B627E566C0AQ41836611-9BF6963D-0116-4400-83AF-DB5A000A2A52Q42497968-510BD9F2-CD9D-44B9-9A92-BF509880978EQ43111691-263785F2-C064-4950-BA6C-CEBD37303A69Q43650151-15695BC0-C90D-423B-8176-0F1A3C4D31B3Q44444430-A4F0A17A-E4CE-47CB-93E5-51DDD0DD88DCQ45244813-736C8F87-613A-4680-8EE9-2A409252ED34Q47438278-84FEDF8D-EAF9-4AC6-8621-AAC076979741Q47712295-31F5A51D-CC58-4715-9434-460A5DAA48B8Q48358059-715AAB54-EFFE-4133-B9EE-BBCC3E7C7E66Q50488486-9EC9B4B4-290B-49BC-8B9B-F4DCC13A8CA0Q51341585-0BBA0F07-812A-48BC-BB03-323118814039Q52583321-61F54F52-0F7F-48B2-8DB1-A4BA7E1FE78EQ52620370-D2F475F3-7D8A-4FB2-9A8A-59082C80A690Q53098595-A52DA1B6-D456-439C-951D-77477CE8C119
P50
description
hulumtues
@sq
researcher
@en
հետազոտող
@hy
name
Andreas Schober
@ast
Andreas Schober
@en
Andreas Schober
@es
Andreas Schober
@nl
type
label
Andreas Schober
@ast
Andreas Schober
@en
Andreas Schober
@es
Andreas Schober
@nl
prefLabel
Andreas Schober
@ast
Andreas Schober
@en
Andreas Schober
@es
Andreas Schober
@nl
P1053
B-2866-2013
P106
P21
P31
P3829
P496
0000-0001-7798-136X